Marking Breast Cancer Awareness Month, Mankind Pharma highlighted the importance of breast cancer awareness, early detection and timely treatment through its Pink October campaign. The initiative builds on the company’s #1 Million Lives journey, which aims to make cancer awareness more accessible and encourage individuals to take proactive steps towards their health.
Breast cancer awareness is important in encouraging timely medical consultation and improving understanding of the disease. Potential warning signs may include a lump or thickening in the breast, changes in breast size or shape, skin changes, nipple changes or unusual discharge. While these changes may not necessarily indicate cancer, they warrant medical evaluation. Clinical examination and mammography, as appropriate to an individual's age and risk profile, can support early detection.
“Cancer awareness must extend beyond healthcare facilities and become an integral part of how people approach their health. Through our #1 Million Lives initiative, we aim to make reliable health information more accessible and encourage proactive healthcare decisions. Pink October reinforces this commitment by highlighting breast health awareness, early detection and timely medical consultation. We believe sustained awareness efforts can empower individuals and families to make informed decisions about their health,” said Atish Majumdar, Senior President, Mankind Pharma.
Early diagnosis also helps doctors determine an appropriate course of treatment. Diagnostic evaluation and tumour profiling help identify the characteristics of breast cancer and guide treatment decisions. HER2 testing, where indicated, helps determine the HER2 status of a tumour and informs decisions regarding appropriate targeted therapies.
“Recognising unusual changes in the breast and seeking medical advice without delay are important steps towards timely diagnosis. Screening recommendations depend on factors such as age and individual risk, making consultation with a qualified healthcare professional essential. For patients diagnosed with breast cancer, diagnostic assessments and biomarker testing, including HER2 testing where indicated, help guide treatment decisions. Greater awareness can encourage timely evaluation and help patients access appropriate care,” said Dr Rajeev Vijay Kumar, Consultant, Medical Oncologist, BGS Fortis Gleneagles
Launched in June 2026, Mankind Pharma’s #1 Million Lives initiative has included the training of over 500 health workers, while 285 doctors pledged to help protect 1 million families in July. Through Pink October, the company continues to strengthen its focus on preventive oncology and encourage greater awareness of early detection and timely care.
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists.
No comments:
Post a Comment